Backer Marina V, Patel Vimal, Jehning Brian T, Backer Joseph M
SibTech, Inc., Newington, Connecticut 06111, USA.
Bioconjug Chem. 2006 Jul-Aug;17(4):912-9. doi: 10.1021/bc060037u.
Random conjugation of therapeutic or diagnostic payloads to targeting proteins generates functionally heterogeneous products. Conjugation of payloads to an adapter that binds to a peptide tag engineered into a targeting protein provides an alternative strategy. To progress into clinical development, an adapter/docking tag system should include humanized components and be stable in circulation. We describe here an adapter/docking tag system based on mutated fragments of human RNase I that spontaneously bind to each other and form a conjugate with a disulfide bond between complimentary cysteine residues. This self-assembled "dock and lock" system utilizes the previously described fusion C-tag, a 1-15 aa fragment of human RNase I with the R4C amino acid substitution, and a newly engineered adapter protein (Ad-C), a 21-127-aa fragment of human RNase I with the V118C substitution. Two vastly different C-tagged recombinant proteins, human vascular endothelial growth factor (VEGF) and a 254-aa long N-terminal fragment of anthrax lethal factor (LFn), retain functional activities after spontaneous conjugation of Ad-C to N-terminal or C-terminal C-tag, respectively. Ad-C modified with pegylated phospolipid and inserted into the lipid membrane of drug-loaded liposomes (Doxil) retained the ability to conjugate C-tagged proteins, yielding targeted liposomes decorated with functionally active proteins. To further optimize the system, we engineered an adapter with an additional cysteine residue at position 88 for site-specific modification, conjugated it to C-tagged VEGF, and labeled with a near-infrared fluorescent dye Cy5.5, yielding a unique functionally active probe for in vivo molecular imaging. We expect that this self-assembled "dock and lock" system will provide new opportunities for using functionally active proteins for biomedical purposes.
将治疗性或诊断性有效载荷随机偶联至靶向蛋白会产生功能异质性产物。将有效载荷偶联至与工程改造到靶向蛋白中的肽标签结合的衔接子提供了一种替代策略。为了推进到临床开发阶段,衔接子/对接标签系统应包含人源化成分且在循环中稳定。我们在此描述一种基于人核糖核酸酶I突变片段的衔接子/对接标签系统,该片段可彼此自发结合并形成共轭物,在互补半胱氨酸残基之间形成二硫键。这种自组装的“对接与锁定”系统利用了先前描述的融合C标签,即具有R4C氨基酸取代的人核糖核酸酶I的1 - 15个氨基酸片段,以及一种新设计的衔接子蛋白(Ad - C),即具有V118C取代的人核糖核酸酶I的21 - 127个氨基酸片段。两种差异极大的带有C标签的重组蛋白,人血管内皮生长因子(VEGF)和炭疽致死因子(LFn)的254个氨基酸长的N端片段,在Ad - C分别与N端或C端C标签自发偶联后仍保留功能活性。用聚乙二醇化磷脂修饰并插入载药脂质体(阿霉素脂质体)脂质膜中的Ad - C保留了与带有C标签蛋白偶联的能力,产生了装饰有功能活性蛋白的靶向脂质体。为了进一步优化该系统,我们设计了一种在88位带有额外半胱氨酸残基用于位点特异性修饰的衔接子,将其与带有C标签的VEGF偶联,并用近红外荧光染料Cy5.5标记,产生了一种用于体内分子成像的独特功能活性探针。我们期望这种自组装的“对接与锁定”系统将为将功能活性蛋白用于生物医学目的提供新机会。